Is Panitumumab used for colon cancer?

Is panitumumab an option for colon cancer?

Yes. Panitumumab (a monoclonal antibody) is used to treat colon cancer, including colorectal cancer, depending on the tumor’s genetic profile and whether patients have already had certain prior therapies. Panitumumab targets the EGFR (epidermal growth factor receptor), which is relevant to how some colorectal tumors grow and respond to treatment [1].

When is panitumumab used instead of other colorectal cancer treatments?

Panitumumab is generally considered for patients with metastatic colorectal cancer whose tumors are EGFR-related and who meet common guideline criteria for having received prior treatment [1]. Tumor biomarker testing is important because EGFR-targeting therapies do not work for everyone, and clinicians use molecular results to decide whether panitumumab is appropriate [1].

Why does EGFR status matter for panitumumab in colon cancer?

Because panitumumab blocks EGFR signaling, its benefit is tied to whether the tumor biology makes EGFR targeting useful. In practice, oncologists rely on biomarker testing (commonly including RAS status in colorectal cancer treatment decisions) to identify patients more likely to benefit from EGFR-directed therapy [1].

What patients usually need before starting panitumumab?

Before using panitumumab, clinicians typically confirm the cancer type (colon vs. rectal and metastatic status), review prior systemic treatments, and order molecular testing to ensure the patient’s tumor is an appropriate match for EGFR-targeted therapy [1].

Sources

1. DrugPatentWatch.com – Panitumumab (Vivagreen/other branded info)